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Abstract
An asymmetric total synthesis of the aminocyclopentitol pactamycin is described, which delivers
the title compound in 15 steps from 2,4-pentanedione. Critical to this approach was the
exploitation of a complex symmetry-breaking reduction strategy to assemble the C1, C2, and C7
relative stereochemistry within the first four steps of the synthesis. Multiple iterations of this
reduction strategy are described, and a thorough analysis of stereochemical outcomes is detailed.
In the final case, an asymmetric Mannich reaction was developed to install a protected amine
directly at the C2 position. Symmetry-breaking reduction of this material gave way to a
remarkable series of stereochemical outcomes leading to the title compound without recourse to
non-strategic downstream manipulations. This synthesis is immediately accommodating to the
facile preparation of structural analogs.
INTRODUCTION
Nature continues to test the state of the art in organic synthesis by providing chemists with
both structurally complex and biologically relevant molecules. Construction of these natural
products often requires the expansion of known synthetic methods to previously unreported
substrate classes or the development of new approaches for the assembly of natural
frameworks.1 Isolated in 1961 from Streptomyces pactum var. pactum, pactamycin (1)
remains one of the most complex aminocyclopentitol antibiotics known, bearing a
remarkable array of unique functionality and exceptional bioactivity.2
Pactamycin exhibits activity against both Gram-positive and Gram-negative bacteria and is a
powerful antitumor, antiviral, and antiprotozoal agent. By acting as universal inhibitor of
translocation, pactamycin is known to inhibit protein synthesis via a specific binding event
within the 30S ribosomal subunit.4 Cytotoxicity levels as high as IC50 = 53 nM against
certain human cell lines have hindered its medicinal development;5 however, a number of
biosynthetically-engineered congeners have been prepared which display diminished
toxicity. These data have reignited promise for the investigation of structure-activity
relationships (SAR) of 1 towards the goal of obtaining a useful drug molecule.7 Thus, the
necessity of a practical and flexible synthesis of 1 is paramount for the success of such
endeavors.
Pactamycin bears a densely-functionalized cyclopentane core featuring six contiguous
stereogenic centers, three of which are fully-substituted.8 Unusual dimethylurea, aniline, and
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salicylate functional groups adorn the core structure, presenting numerous synthetic
challenges. These issues have been addressed in a number of approaches as synthetic
interest in pactamcyin has flourished over the past decade. Hanessian and coworkers
reported the landmark total synthesis in 2011,9,10 and Isobe, Knapp, Looper, Nishikawa, and
our group have disclosed access to advanced core intermediates by varying methods.11–15
An inspection of these approaches reveals two common challenges one faces in assembling
the core structure: i) execution of chemo- and stereoselective reactions in a highly congested
chemical environment and ii) the method by which the unusual functionality of 1 is
introduced. The Hanessian group observed of numerous side reactions due to functional
group propinquity.9,10 Looper and Haussener also noted the importance of the order in
which functional group manipulations were executed.13 Approaches to introducing the
unique C1 dimethylurea have heretofore relied largely upon the use of oxazoline or
oxazolidinone protecting groups, necessitating downstream deprotection and chemoselective
acylation. In the development of a synthesis plan, we took note of these issues and sought to
develop a synthesis of 1 that rapidly assembled the core structure and incorporated all
unique functionality in the absence of non-strategic redox and protecting group
manipulations.16
In 2012, we presented an initial report on our efforts toward a synthesis of 1,15 and earlier
this year this work culminated in a 15-step asymmetric total synthesis.17 Herein, we present
a full account of our studies on pactamycin encompassing a modification of our original
route to accommodate early-stage incorporation of the C2 amine functionality. A symmetry-
breaking reduction for rapid access to the C1/C2/C7 stereotriad was developed, and an
emphasis was placed on incorporating pactamycin’s unique functionality in its final form to
obviate downstream functional group adjustment or protecting group manipulation. This
flexible route, we surmised, would provide access to 1 in a manner amenable to the
synthesis of analogs for biological examination.
Our original retrosynthetic disconnection began with simplification of 1 to functionalized
cyclopentane 2 (Scheme 1). C2 (allylic) functionalization, C4 hydroxylation, and C3 aniline
installation might be possible from a C3-C4 alkene in cyclopentene 3, a compound that was
expected to be accessed by ring-closing metathesis (RCM). The requisite precursor would be
derived from nucleophilic addition to methyl ketone 4. We surmised that this addition could
occur either by inter- or intramolecular nucleophile delivery, the latter facilitated by
attachment to the C7 secondary alcohol. Two approaches to β-hydroxyketone 4 were
envisioned, dependent upon the identity of the R-substituent. For R = OMe (5), we proposed
an enantioselective Tsuji-Trost allylation of ketoester 7 followed by diastereoselective
ketone reduction and ester → ketone conversion.15,18 Alternatively, if R = Me (6), we would
invoke an enantioselective, symmetry-breaking diketone monoreduction, exploiting the
hidden symmetry (see outlined region in Scheme 1) we perceived in the northeast quadrant
of 1.19 Critical to our strategy in either case was the early-stage installation of the
dimethylurea functionality in its final, native form, an approach divergent from those
previously reported. α-Ureidodicarbonyls 7 or 8 would serve as our points of origin,
synthesized from commodity chemicals (methyl acetoacetate 9 or 2,4-pentanedione 10,
respectively).
A summary of our initial efforts is outlined in Scheme 2.15 Ester 11, prepared via the
strategy outlined in Scheme 1, was treated with Me3SiCH2Li to afford β-silyloxyketone 12
poised for nucleophilic addition. From 12, a screen of nucleophiles and conditions were
investigated for access to the requisite C5 alcohol; however, while addition of a model 2-
propenylmetal nucleophile mediated by CeCl3 proceeded in good yield, this reaction gave
consistent preference for the undesired epimeric C5 configuration (13). This stereochemical
outcome necessitated the synthesis of ketone 14, which upon methide addition mediated by
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CeCl3, provided the desired C5 stereochemistry with >20:1 diastereoselection. This
intermediate was then elaborated to 15 in three steps. Experiments directed toward
installation of the C2 primary amine from 15 or its derivatives were extensively investigated




While the above route was scalable and effective for accessing advanced intermediate 15,
the synthesis of ketone 14 required a number of non-strategic redox and protecting group
manipulations and lacked efficiency. As a result, we sought a streamlined approach to its
synthesis. Cognizant of the undesired stereoselectivity encountered in intermolecular
addition to methyl ketone 12, we envisaged that an intramolecular addition might provide
the opposite facial preference. Delivery of a tethered nucleophile from the C7 hydroxyl
followed by reduction and ring-closing metathesis would intercept our previous intermediate
15. This intermediate could be synthesized from our proposed enantioselective
desymmetrization strategy from urea 6, the diketone analog of 5.
The diketone reduction precursor 6 was prepared in three steps (Scheme 3). The reaction of
2,4-pentanedione 10 with para-acetamidobenzenesulfonyl azide (pABSA)20 and Et3N
afforded the corresponding diazoketone in nearly quantitative yield. An N–H insertion
reaction analogous to that used in our previous studies delivered α-ureidodiketone 8 in 67%
yield,21 and Tsuji-Trost allylation provided the necessary diketone precursor 6 in 81% yield.
Working first to optimize the racemic reaction, we began screening reducing agents and
conditions for selectivity. Gratifyingly, LiAl(OtBu)3H (LTBA) emerged early in our
evaluation, providing β-hydroxyketone (±)−17 in 75% yield with >20:1 diastereoselection.
The desired stereochemistry was confirmed via the TBS protection of keto alcohol 17 and
direct comparison with 12, which had been independently synthesized via our previous
route.15 We speculate that this reduction proceeds via chelated structure 16 in which steric
demand of the dimethylurea functionality directs hydride addition to the least hindered face
of the enantiotopic ketones, delivering (±)−17 in high selectivity.
From β-hydroxyketone 17, we began investigating intramolecular additions to the C5
ketone. We were encouraged by the work of Crimmins and coworkers in the use of
organocuprate nucleophiles for initiating intramolecular, alkylative cyclizations and
surmised that an appropriately selected pronucleophile on the C7 hydroxyl could provide the
desired reactivity.22 Thus, acylation of monoalcohol 17 with 2-butynoic acid delivered
ynoate 18 in 79% yield. This esterification set the stage for the proposed cyclization.
Me2CuLi emerged from a screen of known conjugate nucleophiles and conditions to deliver
lactone 19 in 53% yield and 3:1 dr. The desired relative configuration of the C1/C5/C7
stereotriad was confirmed by nOesy analysis.
At this juncture, only reduction remained to provide triol 20; this intermediate would
effectively intercept the synthesis of cyclopentanone 15 in a highly efficient manner.
However, an exhaustive screen of reducing agents and conditions failed to provide alcohol
20. Hindered reducing agents such as DIBAL-H and LTBA displayed no reactivity even at
elevated temperatures, while unhindered reducing agents (LiAlH4, Super-Hydride®) resulted
only in complex mixtures or reduction of the dimethylurea functionality. Additionally,
attempts at ring opening of 19 via transesterification to its corresponding ester or thioester
failed to show any desired reactivity.
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Having reached a second impasse, we began to form conclusions regarding our original and
revised strategies. First, early-stage incorporation of the dimethylurea functionality, while a
strategic risk at the onset of this work, had proven useful in directing desirable
stereochemical outcomes in each of our initial routes. The impressive diastereoselectivity
accessed from symmetry-breaking reduction of diketone 6 gave us cause to incorporate this
strategy again in future routes to 1; however, neither our previously reported approach nor
the above strategy addressed a major problem facing the endgame of our synthesis, namely,
the late-stage installation of the primary amine at C2. In devising a new approach, we
envisioned enantioselective installation of C2 functionality on ureidodiketone 8 prior to the
symmetry-breaking reduction (Scheme 4). Monoreduction of this substrate would provide
access to the C1/C2/C7 stereotriad within the first 4 steps of the synthesis, from which
strategic manipulation of the available functional handles might give expedient access to 1.
Beginning from the previously synthesized α-ureidodiketone 8, an enantioselective Tsuji-
Trost allylation with difurylidene acetate 21 would install a 2-furyl group at the C2 center
(22); we felt that this group could function as an amine surrogate via downstream oxidative
cleavage and Curtius rearrangement.24 Since the ideal functionality at C2 would be the
amine itself, a catalytic, asymmetric Mannich reaction of 8 with a strategically configured
imine such as 23 was projected to deliver diketone 24 with carbamateprotected amine
installed directly at C2.25
In both the allylation and Mannich scenarios, enantioselective formation of the C2
asymmetric center would establish the lone stereochemical element that would be
responsible for all subsequent diastereoselective manipulations. The ensuing
diastereoselective symmetry-breaking monoreduction of a chiral diketone would be the key
for controlling the C1/C7 configurations and would require effective guidance from the
initially-installed C2 stereocenter. The identities of the alkene termini in the generic
structures 21 and 23 can be disregarded since downstream operations would purge these
functionalities. Both of these proposed pathways would deliver the entire core skeleton of 1
within the first 3 steps. Equipped with these new hypotheses, we began pursuing each in
parallel.
C2-Furan Approach
Our first challenge in realizing the Tsuji-Trost allylation approach was the synthesis of the
allylic acetate 21, which surprisingly appears to be a new compound (Scheme 5). To this
end, reduction of difurylpropenone 25 afforded the corresponding alcohol 26; however,
upon concentration of the crude mixture this product rapidly decomposed. The observed
decomposition was unexpected since this compound had been previously reported no note
had been made regarding its instability.26 A screen of conditions designed to circumvent this
problem revealed that NaBH4 reduction of 25 followed by immediate acylation using Et2O
as the solvent provided 21 in crude form.27 Acetate 21 was also found to be unstable, but
could be stored in solution for up to 30 d at 0 °C.
With acetate 21 in our possession, the reaction of diketone 8 with difurylidene acetate 21
under the previously optimized allylation conditions afforded C2-functionalized diketone (±)
−27 in 80% yield. From this compound, we began to examine conditions by which we might
effect symmetry-breaking reduction. Monoreduction of the chiral diketone 27 presents a
more complicated problem than the reduction of diketone 6, since four diastereomeric
products can result from the former. Exposure of diketone 27 to our previously optimized
desymmetrization conditions (LTBA, THF, −40 °C) resulted only in retro-aldol
decomposition. A screen of reducing agents revealed that the reaction of 27 with LiAl(OtBu)
(iBu)2H (LDBBA)28 afforded mono-alcohol 28 with moderate diastereoselectivity (4:1 28:Σ
other diastereomers). While the reduction of diketone 6 (lacking any C2 substituent)
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required warmer temperatures and extended reaction times, reduction of 27 was complete
within 10 min at −78 °C. An X-ray diffraction study of the major diastereomer confirmed
the exact relative configuration needed for elaboration to 1. While we envision a chelation
mode similar to transition structure 16 might be taking place in this reduction, the
involvement of the C2 furan in directing the C1/C7 relative configuration and its dramatic
effect on the reactivity are not well understood.
Having accessed this key intermediate, we proceeded to test conditions for functionalization
of the C5 methyl ketone. Based on our previous work,15 we anticipated potential
stereoselectivity and reactivity problems associated with nucleophilic addition to the C5
carbonyl and accordingly decided to invoke the ability of 28 to participate in enolate
chemistry. Silyl protection of β-hydroxyketone 28 proceeded smoothly to deliver ketone 29
in 96% yield. The lithium enolate derived from 29 reacted with ethyl cyanoformate to
provide β-ketoester 30 in 80% yield.29 To access the cyclic core of 1 from this functionality,
we proposed two parallel strategies: i) alkene oxidative cleavage followed by aldol
condensation or ii) α-methylenation with subsequent RCM. As these routes were pursued,
however, it was quickly found that furan 30 was not compatible with standard oxidative
cleavage conditions (O3, Johnson-Lemieux, RuCl3, etc.), giving only complex mixtures or
starting material decomposition. Turning to the metathesis strategy, we began investigating
α-methylenation protocols. Using the conditions recently reported by Connell and
coworkers, treatment of 30 with (HCHO)n and diisopropylammonium trifluoroacetate30
afforded the undesired Diels-Alder adduct 31, effectively rendering our RCM approach
unfeasible. These results cast doubt as to whether our proposed C2-furan approach would
provide access to 1. In addition, the problems encountered in attempted oxidative cleavage
of ketoester 30 gave us concern as to whether a late-stage unmasking of C2-furan could be
realized. With these data in hand, we turned our attention toward developing a route to 1
from an early-stage Mannich reaction.
C2-Carbamate Approach
Our strategy for direct installation of a protected amine at C2 was inspired by the work of
Schaus and coworkers wherein cinchona alkaloids catalyzed 1,3-dicarbonyl Mannich
addition to carbamoyl aldimines. Expansion to our system would involve a new class of
nucleophile possessing α-ureido functionality (Scheme 6).25 Also crucial to the success of
this method would be selection of the appropriately-protected imine electrophile. In the
event, we proceeded with Cbz-protected cinnamyl imine 32 and began testing conditions for
the Mannich reaction. Working first in the racemic series, the reaction of α-ureidodiketone 8
with imine 32 in the presence of catalytic quantities of Hünig’s base delivered Mannich
product (±)−33 in 90% yield. With the feasibility of this bond construction established,
focus turned to finding a suitable chiral catalyst for the reaction. An extensive screen of
known Mannich reaction promotors31 revealed cinchonidine to be a superior catalyst,
providing (+)−33 in nearly quantitative yield with 84:16 er. Upon trituration, crystalline
racemic 33 could be removed by filtration, leaving highly enantioenriched (+)−33 in 70%
yield and 98:2 er. Unsure of the enantiomer’s configuration, we proceeded with optimization
of this route with racemic material.
From functionalized dicarbonyl 33, we turned towards assembly of the C1/C2/C7 stereotriad
via symmetry-breaking reduction (Scheme 7). Referring to our previously optimized
conditions in the C2-unsubstituted case, monoreduction of 33 with LTBA at −35 °C
provided β-hydroxy ketone 34 in 72% yield with high diastereoselectivity (>10:1 34:Σ other
diastereomers). Efforts to determine the relative configuration of this monoalcohol were
hampered, however, when initial studies toward accessing a crystalline derivative proved
unsuccessful. Turning to spectroscopic methods, ozonolysis of the styrene provided lactol
Sharpe et al. Page 5













derivative 35 from which nOesy analysis suggested the relative configuration of the C1/C2/
C7 stereotriad illustrated in Scheme 8.
Stereochemical Analysis
With this tentative structure in hand, we began to analyze the stereochemical outcome and
its ramifications. For planning purposes, we included both enantiomeric series in this
analysis based on the assumption that either could be accessible via the catalytic,
asymmetric Mannich addition. β-Hydroxyketone (+)−34 is epimeric at C2 relative to
pactamycin (1), a problem for which a solution was not immediately obvious in light of our
projected metathesis-based synthetic plan. Alternatively, the enantiomeric form (–)−34
presents C1 and C2 in the correct pactamycin configuration, but is a product resulting from
incorrect diastereotopic ketone site selectivity in the desymmetrization. Although this was a
discouraging initial result, we retained some measure of confidence in our symmetry-
breaking approach to 1 and began pursuing myriad strategies in parallel for the elaboration
of diketone 33 to our desired reduction diastereomer.
We first pursued an exhaustive screen of reducing agents and conditions in hopes that
reagent control would provide stereoselectivity different to that observed using LTBA.
Monoreduction with a number of bulky hydride sources (L-Selectride®, LDBBA, Red-Al®,
DIBAL-H) resulted only in the formation of stereoisomer 34 in lower yields. Unhindered
hydride sources (LiAlH4, Super Hydride, NaBH4), gave only minimal amounts of 34
accompanied with retro-aldol decomposition pathways. Finally, alternative reduction
pathways (enzymatic reduction, transfer hydrogenation) gave no promise for delivering
diastereoselectivity different to that observed in LTBA reduction of diketone 34. These
unsuccessful efforts led us to the conclusion that this reduction was proceeding with
virtually complete substrate control, and as a result, direct reduction strategies of 33 towards
the desired diastereomer were abandoned.
In an effort to alter the apparent conformational bias associated with the acyclic structure 33,
the diketone was engaged as its derived cyclic iodoimidate 36 through the action of I2 and
Na-HCO3. Subsequent monoreduction of diketone 36 followed by retrocyclization
(mediated by Zn/HOAc) gave the acyclic hydroxy ketone 37 in 61% yield over two steps.
Ketone 37 is a diastereomer different from that accessed via LTBA reduction of 33. We
immediately began work in establishing its stereochemical identity; however, nOesy
analysis by a strategy analogous to that used for 34 was inconclusive.
Concurrent with these studies, we pursued an alternate strategy from the perspective of (–)
−34. Namely, if the original monoreduction product could be further reduced to its
corresponding diol (syn or anti), a site selective oxidation might deliver the desired C1/C2/
C7 configuration. To this end, a screen of conditions revealed that direduction of 33 with
excess LDBBA afforded diol 38 as a 3:1 mixture of separable diastereomers. The major
isomer was revealed to be the 1,3-trans diol via nOesy and 13C NMR analysis of the derived
acetonide 39.32 Control experiments revealed that this reduction proceeds via the
intermediacy of β-hydroxyketone 34. Consequently, the relative stereochemistry at C2 was
assigned according to that shown in alcohol 34.
With diol 38 in hand, we began evaluating oxidants for symmetry-breaking oxidation.
Treating diol 38 with Dess-Martin periodinane (DMP) showed complete selectivity for
oxidation of a single site, returning the original hydroxyketone 34. Alternatively,
tetrapropylammonium perruthenate (TPAP) gave preference for the opposite alcohol,
delivering monoalcohol 37 whose spectral characteristics matched those of the compound
prepared via the iodoimidate. The ability to access 37 from this route enabled us to assign its
Sharpe et al. Page 6













relative stereochemistry, which had previously remained ambiguous via nOesy analysis of
its derivatives.
It is germane to emphasize at this juncture that the above analysis hinged in its entirety on
the nOesy analysis of 35, which was suggestive of the illustrated structure, but not
unequivocal. Because it was so easily accessible, we made the conscious decision to move
forward in our synthetic plan with (+)−34 in the interest of evaluating the chemical viability
of our remaining strategy, despite (or because of!) the absence of an unambiguous stereo-
chemical assignment. It was our hope that rigorous stereochemical proof would be realized
via a suitable crystalline derivative later in the route and that the chemistry developed during
those studies could be effectively translated to whatever diastereomer was needed.
Cyclopentane Core
Silyl protection of (+)−34 under typical conditions proceeded smoothly, delivering β-
silyloxy ketone 40 in 84% yield (Scheme 8). Carboethoxylation of 40 under the previously
optimized conditions (cf. 29 → 30) proceeded uneventfully to deliver the corresponding
ketoester in good yield; however, this intermediate could never be successfully advanced
despite extensive efforts.33 Accordingly, we began to investigate routes by which we might
directly install the requisite C4 hydroxymethylene in its correct oxidation state for
elaboration to 1. This approach would deliver a less activated β-hydroxyketone for
subsequent intramolecular condensation. Literature examples for the use of formaldehyde as
an aldol electrophile in complex total synthesis are limited. Trost and coworkers have
demonstrated its use in their synthesis of corianin.34 The Cao group likewise has shown the
use of CH2O in aldol reactions en route to a total synthesis of malyngamide U.35 After
significant experimentation in our system, we found that bubbling gaseous CH2O (generated
by the pyrolysis of paraformaldehyde) through a solution of the lithium enolate of 40 at −45
°C furnished the desired primary alcohol 41 in 70% yield. Subsequent styrene ozonolysis
delivered the corresponding crude α-carbamoyl aldehyde 42 poised for intramolecular
condensation. NaOMe emerged as a superior promoter from our screen of conditions,
delivering cyclopentenone 43 in 50% yield from 41. This transformation was rendered
completely ineffective if the C6 hydroxymethylene was protected.36 Fortunately,
elimination of H2O strongly favors the formation of the endocyclic alkene over its
constitutional isomer, the α-methylidene cyclopentanone.
With cyclopentenone 43 in hand, only C5 nucleophilic addition, C4 hydroxylation, and
installation of the C3 aniline remained to complete the core structure of 1. An epoxidation/
nucleophilic aniline ring-opening sequence was pursued to access the trans-anilinoalcohol,
inspired by a related approach by Hanessian and coworkers.9,10 We surmised that addition
of a suitable methide nucleophile to the C5 ketone would install the final stereogenic center.
Our experiments revealed that the order of these steps and the identity of the C6
hydroxymethylene protecting group were critical. Thus, treatment of enone 43 with NaOH/
H2O2 delivered epoxy-alcohol 44 in 80% yield with high diastereoselectivity. As in the case
of the intramolecular aldol condensation (42 → 43), the reaction was ineffective if the C6
hydroxyl was protected. We then turned our attention to installation of the C5 methyl group.
In the event, the sterically-demanding TBDPS group37 was found to be necessary to provide
the desired stereoselectivity and withstand the reaction conditions for nucleophilic addition.
Protection of 44 occurred uneventfully to provide TBDPS-ether 45 in 76% yield and treating
this ketone with MeMgBr at 0 °C provided alcohol 46 (diastereoselection >10:1).
Stereochemical Outcome
Having arrived at an intermediate bearing all six of pactamycin’s stereocenters, we began
aggressively pursuing a crystalline intermediate to confirm (or disprove) our earlier
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stereochemical analyses. Carboxybenzyl deprotection of 53 occurred under hydrogenolysis
conditions to deliver the corresponding primary amine, which crystallized readily (Figure 2).
X-ray analysis of this derivative confirmed the desired relative stereochemistry at all six
centers.
This surprising confirmation of correct stereochemistry led us to a number of conclusions
regarding the observed results. With regard to the C5-methylation, nucleophile addition to
the convex surface of similar oxabicyclo[3.1.0]hexanone systems is well documented; in our
system, this trajectory would have delivered the incorrect C5 configuration (Scheme 9).
Indeed, Hanessian and coworkers witnessed exclusively convex surface addition of a
methide nucleophile to ketone 47 in their total synthesis of 1.9,10 A five-step sequence from
48 provided the correct epoxide stereochemistry for synthesis completion. Greaney and
coworkers likewise observed this facial preference in the addition of an alkyllithium
nucleophile to ketone 49 in their syntheses of merrilactone A and anislactone A.38 In our
system, however, this inherent preference was seemingly overridden, delivering the desired
stereochemistry at C5. In the present case, we speculate that this selectivity is observed at
least in part due to direction by the C1-dimethylurea, providing additional support to the
decision to incorporate this functionality in its native form early in the synthesis.
Furthermore, the presence of two large silyl groups on the convex face of epoxide 45 might
serve to block the undesired facial approach.
The presence of the desired C1/C2/C7 stereotriad in 46 seemed at odds with our original
stereochemical assignment of hydroxyketone 34 based on nOesy analysis of lactol derivative
35; however, conscious of the fact that the C2 stereocenter had potentially become
configurationally labile in the form of aldehyde 42, we questioned whether epimerization
had taken place during base-promoted condensation to deliver the desired C2 configuration.
We devised a deuterium labeling experiment to examine the possibility of this pathway
(Scheme 10).
Treating α-carbamoyl aldehyde 42 with NaOMe in CD3OD using the optimized conditions
afforded enone 43 with complete incorporation of deuterium at C2. When this experiment
was conducted at −10 °C for the same time duration, a complex mixture of products was
observed by 1H NMR spectroscopy. Resubmission of this unpurified complex mixture to the
reaction conditions at 0 °C afforded enone 43 with complete D-incorporation. Finally,
submission of the product enone 43 to NaOMe in CD3OD returned the starting material with
no deuterium incorporation. These results clearly indicate that the C2 methine was
undergoing proton exchange prior to the condensation; however, unambiguous confirmation
of epimerization required X-ray analysis of an upstream intermediate. Returning to our
previous attempts at derivatization of hydroxyketone (+)−34 led to the synthesis of
enantioenriched benzoate derivative 51, which crystallized readily. X-ray analysis of 51
established the sense of induction in the asymmetric Mannich addition and confirmed the
existence of the incorrect C2 configuration in the desymmetrization product 34. In light of
this result, we speculate that formation of the observed monoreduction diastereomer 34
arises via the chelated structure 52, a proposal modeled after a similar case reported by
Davis and co-workers (Scheme 11).39 Preferential re-face addition of hydride to pseudo-
chair conformer 52 gives rise to the observed monoreduction diastereomer.
From the complete set of experiments relating to the pactamycin stereochemistry problem,
the following conclusions can be made (Scheme 12): i) our original stereochemical
assignment of hydroxyketone 34 via nOesy analysis of 35 was correct; ii) the
enantioselective Mannich addition (8 → 33) had yielded the incorrect enantiomer nominally
required for elaboration to 1; and iii) this stereochemical “mistake”, compulsory for
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directing the correct C1/C7 stereochemistry in the symmetry-breaking reduction (33 → 34),
was later corrected via epimerization in the aldol condensation (42 → 43). Incredibly, this
series of events had taken place unbeknownst to us until crystallographic evidence of a
much later intermediate led us to suspect the validity of our original stereochemical analysis.
Completion of Synthesis
Our plan to complete the synthesis began with the development of a Lewis acid-promoted
aniline epoxide opening to install the required m-acetylaniline in 1. A similar approach had
been employed by Hanessian and coworkers for introduction of the C3/C4 trans-
anilinoalcohol whereupon the requisite aniline was incorporated via its m-propenyl
derivative.9,10 The necessary acetophenone was later revealed via oxidative cleavage of the
olefin. By contrast, we hoped that the required aniline could be installed in its native form,
obviating downstream introduction of the ketone. After considerable experimentation, we
found that addition of m-acetylaniline to epoxide 46 promoted by Sc(OTf)3 delivered the
desired trans-aminoalcohol 53 in 66% yield. It is important to note that while this
transformation proceeds in moderate yield, the use of more electron-rich anilines in the
reaction delivers the corresponding epoxide-opened products in high yield, a valuable result
as this step is a crucial branch point for analog synthesis. Silyl deprotection proceeded
readily upon treatment of 53 with tetrabutylammonium fluoride (TBAF), providing tetraol
54 in 90% yield. Installation of the salicylate moiety was accomplished via treatment of
alcohol 54 with an in-situ generated ketene electrophile derived from cyanomethylester
55.40 This left only removal of the C2 protecting group to complete our synthesis. Cbz-
deprotection was effected readily upon hydrogenation of 56 in the presence of Pearlman’s
catalyst to deliver pactamycin (1) in 82% yield.41
CONCLUSION
In summary, we have detailed the entirety of our efforts toward the synthesis of pactamycin,
culminating in an asymmetric, 15-step total synthesis in 1.9% overall yield from commodity
chemical 2,4-pentanedione. Emphasis was placed on incorporation of all unique
functionality (dimethylurea, aniline, salicylate) in its native form for minimization of
protecting group manipulations. Revision of our originally published strategy led to the
development of a novel alkylative cyclization for intramolecular delivery of C5
stereochemistry. A need to incorporate C2 functionality early-stage gave rise to the synthesis
of a new difurylidene acetate reagent which was employed in a complex Tsuji-Trost
allylation, and an enantioselective Mannich addition of α-ureidodicarbonyls was developed
via an adaptation of the Schaus conditions.25 A symmetry-breaking reduction was employed
for rapid delivery of the C1/C2/C7 stereotriad in 1, and proposed stereochemical models for
these reductions are presented herein. In the case of the C2-carbamate approach, a thorough
analysis of monoreduction stereochemical outcomes is presented. These studies culminated
with the conclusion that selective oxidation of trans-diol 38 could allow access to a suitable
monoreduction diastereomer of 33 for elaboration to 1. This deduction directed the decision
to move forward in our strategy without unambiguous stereochemical confirmation of
alcohol 34 with the assumption that the necessary relative configuration of 1 could be
realized later in the synthesis. The stereochemical identity of 34 was later unambiguously
determined to be incorrect at C2, although this “stereochemical error” was corrected via
epimerization during a downstream aldol condensation. This fortuitous turn of events
allowed facile access to 1 in the absence of non-strategic stereochemical manipulations. This
route is flexible and immediately amenable to the synthesis of structural analogs as major
functional groups (aniline, salicylate) are incorporated in a late-stage fashion. Studies
towards the preparation of analogs for analysis of structure-activity relationships (SAR) are
ongoing in our laboratory and will be reported in due course.
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X-ray structure of Cbz-deprotected 46; the silyl groups are truncated for clarity. Disorder
exists in the TBS group.
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Initial retrosynthetic analysis for pactamycin
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Previously reported intermolecular addition approach to 1
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Intramolecular addition approach to 15a
aConditions: (a) pABSA, Et3N, CH3CN; 0 °C to rt; (b) Rh2Oct4 (0.4 mol %), 1,1-
dimethylurea, C7H8/DCE (1:1), 80 °C; (c) [allylPdCl]2 (0.5 mol %), rac-BINAP (1.1 mol
%), tBuOK, allyl acetate, C7H8, rt; (d) LiAl(OtBu)3H, THF, −40 °C; (e) 2-butynoic acid,
DMAP (10 mol %), DIC, Et2O, −20 °C to rt; (f) Me2CuLi, Et2O, −78 °C to rt.
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Proposed routes to C2-functionalized desymmetrization precursors
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Desymmetrization of 2-furyl substituted diketone derivative 27 and advancement toward the
synthesis of 1a
aConditions: (a) NaBH4, THF:H2O (1:1), rt; (b) Ac2O, NEt3, DMAP (5 mol %), Et2O, rt; (c)
[allylPdCl]2 (2.5 mol %), rac-BINAP (5.28 mol %), tBuOK, C7H8, rt; (d) LiAl(OtBu)
(iBu)2H, THF, −78 °C; (e) TBSCl, imidazole, CH2Cl2, rt; (f) LDA, THF, − 78 °C, then ethyl
cyanoformate, −78 °C to −20 °C; (g) diisopropylammonium trifluoroacetate, (HCHO)n,
THF, 65 °C.
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Development of a Mannich reaction for installation of C2 functionality
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Studies on symmetry-breaking reduction of 33a
aConditions: (a) LTBA, THF, −35 °C; (b) O3, CH2Cl2, −78; Me2S, rt; (c) I2, NaHCO3, 4Å
MS, 0 °C to rt; (d) LTBA, THF, −10 °C; (e) Zn, AcOH, Et2O:MeOH (1:1), rt; (f) LDBBA,
C7H8, −40 °C; (g) CSA, acetone:dimethoxypropane (1:1), rt; (h) DMP, CH2Cl2, rt; (i)
TPAP, CH3CN, −20 °C.
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Access to cyclopentane core via formaldehyde aldol/condensationa
aConditions: (a) TBSOTf, 2,6-lutidine, CH2Cl2, −78 °C; (b) LDA, THF, −78 °C, then
CH2O(g), −45 °C; (c) O3, −78 °C, CH2Cl2; Me2S, rt; (d) NaOMe, THF:MeOH (4:1), 0 °C;
(e) H2O2 (30% aq.), NaOH (20% aq.), MeOH:CH2Cl2 (7:1), 0 °C; (f) TBDPSCl, NEt3,
DMAP (10 mol %), CH2Cl2, 0 °C to rt; (g) MeMgBr, THF, 0 °C.
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Convex versus concave surface addition of carbon nucleophiles to
oxobicyclo[3.1.0]hexanones
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Deuterium-labeling experiments and unambiguous stereochemical assignment of 34
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Proposed stereochemical model for LTBA reduction of 33
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Completion of the synthesis of pactamycina
aConditions: (a) LTBA, THF, −35 °C; (b) TBSOTf, 2,6-lutidine, CH2Cl2, −78 °C; (c) LDA,
THF, −78 °C, then CH2O(g), −45 °C; (d)O3, −78 °C, CH2Cl2; Me2S, rt; (e) NaOMe,
THF:MeOH (4:1), 0 °C; (f) H2O2 (30% aq.), NaOH (20% aq.), MeOH:CH2Cl2 (7:1), 0 °C;
(g) TBDPSCl, NEt3, DMAP (10 mol %), CH2Cl2, 0 °C to rt; (h) MeMgBr, THF, 0 °C; (i) m-
acetylaniline, Sc(OTf)3, C7H8, 60 °C; (j) TBAF, THF, 0 °C; (k) 55, K2CO3, DMA, rt; (l)
H2, Pd(OH)2/C (50% mass), MeOH, rt
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